Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Merit Medical Systems (MMSI) has provided an update.
On July 1, 2024, Merit successfully acquired the EsophyX® Z+ device and related assets from EndoGastric Solutions, Inc. for $105 million, expanding its portfolio into non-pharmacological treatments for gastroesophageal reflux disease. This strategic acquisition, financed through Merit’s long-term credit facility, also included the assumption or reimbursement of certain liabilities and was backed by a buyer-side representation and warranty insurance policy. Following the deal, Merit signed additional agreements ensuring a smooth transition of the business operations and assets.
Learn more about MMSI stock on TipRanks’ Stock Analysis page.